



Title: Geographical variation in therapy for bloodstream infections due to 
multidrug-resistant enterobacteriaceae: a post hoc analysis of the 
INCREMENT study 
 
Author: Patrick N.A. Harris, M. Diletta Pezzani, Belén Gutiérrez-Gutiérrez, 
Pierluigi Viale, Po-Ren Hsueh, Patricia Ruiz-Garbajosa, Mario Venditti, Mario 
Tumbarello, Carolina Navarro-Francisco, Esther Calbo, Murat Akova, Helen 
Giamarellou, Antonio Oliver, Benito Almirante, Oriol Gasch, Luis Martínez-Martínez, Mitchell J. 
Schwaber, George Daikos, Johann Pitout, Carmen Peña, Alicia Hernández-Torres, Yohei Doi, 
Federico Pérez, Felipe Francisco Tuon, Evelina Tacconelli, Yehuda Carmeli, Robert A. Bonomo, 
Álvaro Pascual, David L. Paterson, Jesús Rodríguez-Baño, the ESGBIS/REIPI/INCREMENT 
group 
 
PII:  S0924-8579(17)30297-2 
DOI:  http://dx.doi.org/doi: 10.1016/j.ijantimicag.2017.08.005 
Reference: ANTAGE 5229 
 
To appear in: International Journal of Antimicrobial Agents 
 
Received date: 30-5-2017 
Accepted date: 1-8-2017 
 
 
Please cite this article as:  Patrick N.A. Harris, M. Diletta Pezzani, Belén Gutiérrez-Gutiérrez, 
Pierluigi Viale, Po-Ren Hsueh, Patricia Ruiz-Garbajosa, Mario Venditti, Mario Tumbarello, 
Carolina Navarro-Francisco, Esther Calbo, Murat Akova, Helen Giamarellou, Antonio Oliver, 
Benito Almirante, Oriol Gasch, Luis Martínez-Martínez, Mitchell J. Schwaber, George Daikos, 
Johann Pitout, Carmen Peña, Alicia Hernández-Torres, Yohei Doi, Federico Pérez, Felipe 
Francisco Tuon, Evelina Tacconelli, Yehuda Carmeli, Robert A. Bonomo, Álvaro Pascual, David 
L. Paterson, Jesús Rodríguez-Baño, the ESGBIS/REIPI/INCREMENT group, Geographical 
variation in therapy for bloodstream infections due to multidrug-resistant enterobacteriaceae: a 
post hoc analysis of the INCREMENT study, International Journal of Antimicrobial Agents 
(2017), http://dx.doi.org/doi: 10.1016/j.ijantimicag.2017.08.005. 
 
This is a PDF file of an unedited manuscript that has been accepted for publication.  As a service 
to our customers we are providing this early version of the manuscript.  The manuscript will 
undergo copyediting, typesetting, and review of the resulting proof before it is published in its 
final form.  Please note that during the production process errors may be discovered which could 






Geographical variation in therapy for bloodstream infections due to 1 
multidrug-resistant Enterobacteriaceae: a post hoc analysis of the 2 
INCREMENT study 3 
 4 
 5 
Patrick N. A. Harrisa*, M. Diletta Pezzanib, Belén Gutiérrez-Gutiérrezc, Pierluigi Vialed, Po-Ren 6 
Hsuehe, Patricia Ruiz-Garbajosaf, Mario Vendittig, Mario Tumbarelloh, Carolina Navarro-7 
Franciscoi, Esther Calboj, Murat Akovak, Helen Giamarelloul, Antonio Oliverm,  Benito 8 
Almiranten, Oriol Gascho,  Luis Martínez-Martínezp, Mitchell J. Schwaberq, George Daikosr, 9 
Johann Pitouts, Carmen Peñat, Alicia Hernández-Torresu, Yohei Doiv, Federico Pérezw, Felipe 10 
Francisco Tuonx, Evelina Tacconelliy, Yehuda Carmeliq, Robert A. Bonomow, Álvaro Pascualc, 11 
David L. Patersona,z, Jesús Rodríguez-Bañoc and the ESGBIS/REIPI/INCREMENT group. 12 
 13 
    14 
a) University of Queensland, UQ Centre for Clinical Research, Brisbane, QLD, Australia 15 
b) Department of Biomedical and Clinical Sciences L. Sacco, III Divisione Malattie Infettive, 16 
University of Milan, Italy 17 
c) Unidad Clínica Intercentros de Enfermedades Infecciosas, Microbiología y Medicina 18 
Preventiva. Hospitales Universitarios Virgen Macarena y Virgen del Rocío, Instituto de 19 
Biomedicina de Sevilla, IBiS/CSIC/Universidad de Sevilla. Seville, Spain 20 
d) Teaching Hospital Policlinico S. Orsola Malpighi, Bologna, Italy 21 
e) National Taiwan University Hospital, National Taiwan University College of Medicine, 22 
Taipei, Taiwan 23 




f) Hospital Ramón y Cajal, Madrid, Spain  24 
g) Policlinico Umberto I, University of Rome La Sapienza, Rome, Italy 25 
h) Catholic University of the Sacred Heart, Rome, Italy 26 
i) Hospital Universitario La Paz-IDIPAZ, Madrid, Spain  27 
j) Hospital Universitari Mútua de Terrassa, Barcelona, Spain; Universitat Internacional de 28 
Catalunya, Barcelona, Spain 29 
k) Hacettepe University School of Medicine, Ankara, Turkey 30 
l) Hygeia General Hospital, Athens, Greece 31 
m) Hospital Universitario Son Espases, Instituto de Investigación Sanitaria de Palma (IdISPa), 32 
Palma de Mallorca, Spain 33 
n) Hospital Vall d’Hebrón, Barcelona, Spain 34 
o) Hospital Parc Taulí, Sabadell, Barcelona, Spain 35 
p) Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain 36 
q) Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Center, Tel 37 
Aviv, Israel, and National Center for Infection Control, Israel Ministry of Health, Tel Aviv, 38 
Israel; Sackler Faculty of Medicine, Tel Aviv University 39 
r) National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece 40 
s) University of Calgary, Calgary, Canada 41 
t) Hospital Universitari de Bellvitge, Barcelona, Spain 42 
u) Hospital Universitario Virgen de la Arrixaca, Murcia, Spain 43 
v) University of Pittsburgh, Pennsylvania, USA 44 
w) Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 45 
Cleveland, Ohio, USA Departments of Medicine, Pharmacology, Biochemistry, Molecular 46 




Biology, and Microbiology, Case Western Reserve University School of Medicine, 47 
Cleveland, Ohio, USA. 48 
x) Hospital da Universidade Federal do Parana, Brazil 49 
y) Tübingen University Hospital and Center for Infection Research (DZIF), Tübingen, 50 
Germany 51 
z) Wesley Medical Research, The Wesley Hospital, Brisbane, Australia 52 
 53 
 54 
*Corresponding author 55 
Dr. Patrick Harris 56 
University of Queensland, UQ Centre for Clinical Research (UQCCR) 57 
Infection & Immunity Theme 58 
Level 5, Building 71/918 Royal Brisbane and Women’s Hospital 59 
Herston, QLD 4029,  60 
Australia 61 
Tel: +61 7 3346 5476; Fax: +61 7 3346 5598;  62 
Email: p.harris@uq.edu.au 63 
  64 





 Regional variation exists in therapy for BSI caused by ESBL-producers or CPE 66 
 Location influenced the empirical use of BLBLIs or carbapenems 67 
 BLBLI use for ESBL-producers or combination therapy for CPE also varied by location 68 
 Variation by location remained after adjustment for clinical factors 69 
 These data may help clinical trial design and antimicrobial stewardship efforts 70 
Abstract 71 
We aimed to describe regional differences in therapy for bloodstream infection (BSI) caused 72 
by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) or 73 
carbapenemase-producing Enterobacteriaceae (CPE). 1,482 patients in 12 countries were 74 
included from an observational study of BSI caused by ESBL-E or CPE. Multivariate logistic 75 
regression was used to calculate adjusted odds ratios (aORs) for the influence of country of 76 
recruitment on empirical use of β-lactam/β-lactamase inhibitors (BLBLI) or carbapenems, 77 
targeted use of BLBLI for ESBL-E and use of targeted combination therapy for CPE. The use of 78 
BLBLI for empirical therapy was least likely in sites from Israel (aOR 0.34, 95% CI 0.14-0.81), 79 
Greece (aOR 0.49, 95% CI 0.26-0.94) and Canada (aOR 0.31, 95% CI 0.11-0.88) but more 80 
likely in Italy (aOR 1.58, 95% CI 1.11-2.2) and Turkey (aOR 2.09, 95% CI 1.14-3.81), compared 81 
to Spain as a reference.  Empirical carbapenems were more likely to be used in sites from 82 
Taiwan (aOR 1.73, 95% CI 1.03-2.92) and USA (aOR 1.89; 95% CI 1.05-3.39), and less likely in 83 
Italy (aOR 0.44, 95% CI 0.28-0.69) and Canada (aOR 0.10, 95% CI 0.01-0.74).  Targeted BLBLI 84 
for ESBL-E was more likely in sites from Italy. Treatment at sites within Israel, Taiwan, Turkey 85 
and Brazil was associated with less combination therapy for CPE. Although this study does 86 
not provide precise data on the relative prevalence of ESBL-E or CPE, significant variation in 87 
therapy exists across countries even after adjustment for patient factors.  A better 88 




understanding of what influences therapeutic choices for these infections will aid 89 
antimicrobial stewardship efforts.  90 
 91 
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 95 
1. Introduction 96 
Bloodstream infections (BSI) are an important cause of morbidity and mortality worldwide. 97 
Differences in population demography, risk factor distribution and microbiology influence 98 
the incidence of BSI within different countries. Enterobacteriaceae are a major cause of BSI, 99 
with Escherichia coli and Klebsiella pneumoniae as the two most common gram-negative 100 
species isolated from blood cultures both in the community and in health care setting.[1, 2] 101 
Extended-spectrum β-lactamase (ESBL) enzymes confer resistance to 102 
oxyiminocephalosporins and monobactams in additional to penicillins, and have become 103 
widespread among Enterobacteriaceae,[3, 4] with rising trends even in low-prevalence 104 
countries.[5, 6] ESBL-producing organisms often carry other resistance genes thus limiting 105 
choices for effective antimicrobial therapy.[7]  Due to their stability to ESBLs, carbapenems 106 
have been considered the preferred agent for the treatment of serious infections caused by 107 
ESBL-producers,[3] but overuse of carbapenems may provide selection pressure for 108 
carbapenem resistance.[8]  Carbapenem-resistant Enterobacteriaceae (CRE), often resulting 109 
from the acquisition of carbapenemase genes, is now an emerging global public health 110 
threat.[9, 10] Although geographical variation in the prevalence of ESBL-producing 111 
Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE) causing 112 




BSI is well known, it is less clear how this variation influences clinical practice in terms of 113 
selecting empirical or targeted treatment regimens.  114 
 115 
The objectives of this study were to investigate variation across countries in antibiotic 116 
regimens used as empirical or targeted therapy for resistant gram-negative BSI, with the 117 
following hypotheses: (1) regional variation exists in the choice of empirical or targeted 118 
therapy for BSI caused by ESBL-E or CPE; (2) Regional variation exists in the use of β-119 
lactam/β-lactamase inhibitor (BLBLI) agents as targeted therapy for bacteraemia caused by 120 
ESBL-E; and (3) regional variation exists in the use of combination therapy for bacteraemia 121 
caused by CPE.  122 
 123 
2. Material and Methods 124 
2.1 Study design and participants 125 
This was a sub-study of a retrospective international cohort study (INCREMENT project; 126 
ClinicalTrials.gov identifier: NCT01764490) investigating the outcome impact of different 127 
antimicrobial regimens in the empirical and targeted therapy in BSI caused by ESBL-E or CPE 128 
from January 2004 to December 2013.[11] Thirty-seven hospitals from twelve countries 129 
(Spain, Italy, Greece, Taiwan, Turkey, Israel, USA, Argentina, Canada, Germany, Brazil and 130 
South Africa) participated in the INCREMENT project.  Consecutive patients were included if 131 
they had a clinically significant monomicrobial BSI due to either ESBL-E or CPE. Sites were 132 
encouraged to limit inclusion of only 50 ESBL-E cases, but had no limit to CPE cases.  Canada 133 
and Germany only contributed ESBL-E cases, Brazil only submitted CPE cases, whereas all 134 
other sites included both ESBL-E and CPE.  135 
 136 




2.2 Variables and definitions 137 
We defined as “empirical” therapies administrated before the availability of any 138 
microbiological result; among the empirical therapies we considered the first antimicrobial 139 
agent used regardless of later additions or changes. Antibiotic regimens were incorporated 140 
into the following classes: aminoglycosides (amikacin, gentamicin, tobramycin), BLBLIs 141 
(amoxicillin-clavulanate, piperacillin-tazobactam, ticarcillin-clavulanate, ampicillin-142 
sulbactam), cephalosporins (cefepime, cefotaxime, cefuroxime, ceftriaxone, ceftazidime, 143 
cephalothin, cefixime), carbapenems (imipenem, doripenem, meropenem, ertapenem), 144 
colistin or tigecycline-based regimens.  Targeted therapy was defined as the agent selected 145 
once susceptibility results were available; this therapy had to be commenced within 5 days 146 
of the initial positive blood culture and administered for at least 50% of the total treatment 147 
duration. Monotherapy was defined if no other drug with activity against gram-negative 148 
organisms was co-administered, irrespective of isolate susceptibility.  We defined as 149 
inadequate those regimens against which the corresponding bloodstream isolates displayed 150 
a resistant or intermediate profile, using Clinical and Laboratory Standards Institute (CLSI) 151 
guidelines from 2012.[12] ESBL production was screened and confirmed according to CLSI 152 
recommendations;[12] selected ESBLs and all carbapenemases were characterised by 153 
polymerase chain reaction (PCR) and DNA sequencing using established methods at each 154 
local laboratory.  Nosocomial acquisition was defined as occurring when symptoms 155 
associated with bacteraemia occurred >48 hours after admission, or within 48 hours of 156 
discharge.  Otherwise, acquisition was considered to be community-onset.  Additional 157 
demographic and clinical data were collected for all patients, including age, sex, Charlson co-158 
morbidity score[13], Pitt bacteraemia score[14], the presence of severe sepsis or shock[15], 159 
diabetes mellitus, liver cirrhosis, malignancy or renal insufficiency. 160 





2.3 Statistical analysis 162 
Categorical variables were expressed as proportions and compared using Pearson’s χ2 test. 163 
For normally distributed scale variables, means and standard deviations were calculated and 164 
compared by two-sample t-test. For non-parametric data, median and interquartile ranges 165 
(IQR) were calculated and compared using the Wilcoxon rank-sum test.  Potential predictors 166 
for antibiotic choice as the dependent variable were included in a univariate logistic 167 
regression model, with country of recruitment used as the main predictor. Patients who died 168 
before empirical or targeted therapy could be administered or those missing data describing 169 
antibiotic therapy were excluded.  Variables with a p-value of <0.2 and/or with large effect 170 
estimates (Odds Ratios > 2 or < 0.5) in the univariate analysis were included in the 171 
multivariate model (using fixed effects). Odds ratios (ORs) with 95% confidence intervals 172 
were calculated for predictors of empirical carbapenem or BLBLI use, use of BLBLI for 173 
targeted treatment of ESBL-E and for targeted combination therapy of CPE. The multivariate 174 
model was optimized using a stepwise approach, beginning with the univariate model most 175 
strongly associated with choice of antibiotic therapy. The goodness-of-fit of the model 176 
before and after each step was compared using the likelihood ratio test and Akaike’s 177 
information criterion. Variables that did not significantly improve the model fit were not 178 
added to the model. Statistical analysis was performed using Stata 13.1 (StataCorp; TX, USA) 179 
and figures produced using Prism 6 (GraphPad Software; CA, USA). A P-value <0.05 was 180 
considered significant.  181 
 182 
3. Results 183 




A total of 1,482 patients (1,003 with ESBL-E and 479 with CPE) were enrolled from 12 184 
countries, with most cases recruited from sites in Spain (47.2%) (Figure 1). The baseline 185 
patient characteristics are presented in Table 1. Overall CPE accounted for 32.3% (479/1482) 186 
of cases, and were most frequently submitted from Italy (n=115), Spain (n=99), Greece 187 
(n=89) and Taiwan (n=60), whereas Canada and Germany contributed no CPE cases (Figure 188 
1). It should be noted that these proportions reflect case selection and should not be 189 
interpreted as reflecting the true prevalence of resistance in each country. Empirical 190 
antibiotic choices for both ESBL-E and CPE cases and the proportions of isolates testing 191 
susceptible to the chosen regimen are shown in Figures 2A-D. Use of empirical therapy for 192 
ESBL-E and CPE BSI according to source of infection and acquisition status (community vs. 193 
nosocomial) is shown in Figures 3A-D. The use of BLBLI for the targeted treatment of ESBL-E 194 
or targeted combination therapy CPE also varied across countries (Figures 4A-D). For 195 
targeted therapy of ESBL-E, carbapenems were used most commonly across all countries 196 
(478/993, 48.1%), with BLBLIs used less frequently (101/993, 10.1%) (Figure 4A).  Italy 197 
showed the highest use of BLBLIs for ESBL-E (29/132, 22.0%), whereas these were never 198 
used in Germany, Canada, Taiwan or South Africa.  Targeted combination therapy was used 199 
in 44.1% of CPE cases (211/479) (Figure 4B). Carbapenem-based combination therapy of CPE 200 
(i.e. any targeted regimen that included a carbapenem in combination with at least one 201 
other agent) was used in 17.1% (82/479) of cases, and occurred most commonly in Italy 202 
(31/115, 27.0%), Greece (16/89, 18.0%) and Turkey (5/27, 18.5%) but was never used in 203 
Argentina or South Africa, although the total number of CPE treated in these countries was 204 
low (Supplementary Table 1).   Details of agents used in targeted combination therapy for 205 
CPE are presented in Supplementary Table 2.  206 




In a multivariate logistic regression model, using Spain as the reference category (as the 207 
group with the largest number of cases), patients were less likely to receive empirical BLBLI 208 
therapy if they were from Israel (aOR 0.34, 95% CI 0.14-0.81; p=0.015), Canada (aOR 0.31, 209 
95% CI 0.11-0.88; p=0.028) or Greece (aOR 0.49, 95% CI 0.26-0.94; p=0.033), but more likely 210 
in Italy (aOR 1.58, 95% CI 1.11-2.25; p=0.012) or Turkey (aOR 2.09, 95% CI 1.14-3.81; 211 
p=0.016) after adjustment for age, ICU admission, infecting species, acquisition status and 212 
Pitt bacteraemia score (Figure 5A; Supplementary table 3).  Empirical carbapenem use was 213 
more likely for sites within Taiwan (aOR 1.73, 95% CI 1.03-2.92; p=0.038) and the USA (aOR 214 
1.89, 95% CI 1.05-3.39; p=0.032), but less likely in Italy (aOR 0.44, 95% CI 0.28-0.69; p<0.001) 215 
and Canada (aOR 0.10, 95% CI 0.01-0.74; p=0.024) after adjustment for age, ICU admission, 216 
infecting organism, acquisition status and Pitt score (Figure 5B; Supplementary Table 4). The 217 
use of a BLBLI for targeted therapy of ESBL-E was significantly more likely in patients treated 218 
at Italian sites (aOR 3.46, 95% CI 2.00-6.00; p<0.001) after adjustment for age, ICU 219 
admission, infecting genus, acquisition status, the presence of severe sepsis and Pitt score 220 
(Figure 5C; Supplementary table 5).  It is worth noting that use of BLBLI as targeted therapy 221 
was less likely with higher Pitt scores, although the effect was modest (aOR 0.88; 95% CI 222 
0.77-0.99; p=0.038) (Supplementary table 5).   For the use of targeted combination therapy 223 
against CPE, the effect of location was seen for Israel (aOR 0.14; 95% CI 0.04-0.44; p=0.001), 224 
Taiwan (aOR 0.09; 95% CI 0.03-0.24; p<0.001), Brazil (aOR 0.14, 95% CI 0.04-0.45; p=0.001) 225 
and Turkey (aOR 0.26; 95% CI 0.10-0.69; p=0.007) where combination therapy was 226 
significantly less likely to be used after adjustment for source, acquisition status, presence of 227 
liver disease and infecting genus (Figure 5D; Supplementary table 6).      228 
  229 




4. Discussion 230 
In the present study we sought to understand the different therapeutic approaches to BSI  231 
caused by multidrug-resistant Enterobacteriaceae across participant sites according to the 232 
country of recruitment. Considerable geographical variation was seen in choice of therapy, 233 
either when selected empirically or targeted against a known pathogen.  While much of this 234 
might be explained by the background prevalence of resistance, this may not account for all 235 
the variation seen.  236 
 237 
Historical differences in clinical practice or local guidelines across countries are likely to be 238 
strong drivers in routine selection of empirical therapy. A survey conducted in Europe 239 
between 1997-2009 showed significant variation in total outpatient antibiotic use, highest in 240 
Greece (38.6 defined daily doses per 1000 inhabitants per day [DID]) and lowest in Romania 241 
(10.6 DID).[16] Penicillins were the most frequently prescribed class due mainly to an 242 
increase in the use of combinations with β-lactamase inhibitors.[17] Notably, Italy was the 243 
country with the highest use of penicillins followed by Greece.[17] 244 
 245 
A key question of interest was how frequently BLBLIs were used as therapy for BSI caused by 246 
ESBL-E. After adjustment for potential confounding factors, recruitment from sites in Israel, 247 
Canada and Greece was independently associated with less use of BLBLI for empirical 248 
therapy of patients with ESBL-E. In the participant hospitals from Italy and Turkey empirical 249 
BLBLI use was significantly more likely to be used for ESBL-E, even after adjustment.  Not 250 
surprisingly, BSI caused by CPE was associated with less empirical BLBLI use. This may either 251 
reflect prior knowledge of colonisation with multi-resistant organisms, or recognition of 252 
relevant clinical risk factors. Indeed CPE was significantly more likely to be seen in 253 




nosocomial infection than ESBL-E (88.9% vs 50.1%, p<0.001; χ2 test). Empirical carbapenem 254 
use was also less likely in older patients, although this effect size was small (aOR 0.99, 95% CI 255 
0.98-1.00; p=0.029). No other clinical factors, apart from geographical location, were 256 
significantly associated with empirical carbapenem use on univariate or multivariate 257 
analyses.  This is perhaps surprising, given that one might expect carbapenem use to be 258 
more likely in patients with high acuity infections or with greater burden of disease, but this 259 
was not associated with the objective markers of infection severity or co-morbidity that 260 
were measured in this cohort (i.e. Pitt, Charlson scores, co-morbid disease or the presence 261 
of severe sepsis or septic shock).  However, it is possible that additional clinical factors could 262 
influence empirical carbapenem use, which were not measured (e.g. presence of significant 263 
immunosuppression, organ transplant, background rate or antibiotic resistance).  264 
 265 
The burden of CPE and ESBL-E seen in this cohort broadly reflects existing prevalence data 266 
from these countries, but should not be considered an accurate description of national 267 
prevalence data. Within the European Union/European Economic Area (EU/EAA), Greece 268 
and Italy were the two countries with the majority of CPE cases included (see Figure 1). From 269 
2009 to 2014 there has been an increasing trend of the EU/EAA population weighted mean 270 
percentage for carbapenem resistance in K. pneumoniae with the highest rates in Italy, 271 
Greece and Romania.[18] Carbapenem resistance in E. coli in Europe remains generally low 272 
(<0.1%), however a rising trend in resistance to third-generation cephalosporins has been 273 
observed in more than a third of countries.[18] Taiwan, which still has a low prevalence of 274 
CPE,[19] detected carbapenemase genes in 6% of 100 isolates in 2010 and 22.3% of 247 275 
isolates in 2012 in a national surveillance study on carbapenem non-susceptible K. 276 
pneumoniae.[20] In the USA, CDC surveillance systems have reported an increase in the 277 




percentage of Enterobacteriaceae with non-susceptibility to carbapenems.[21] In 2001 278 
approximately 1.2% of the most common Enterobacteriaceae reported to the Nosocomial 279 
Infection Surveillance system were non-susceptible to at least one of the 3 carbapenems; in 280 
2011 that percentage had risen to 4.2% with the greatest increase observed among K. 281 
pneumoniae (from 1.6% to 10.4%).[22] A retrospective cohort study among community 282 
hospitals throughout the south-eastern United States has found an increase in the incidence 283 
of ESBL–E. coli infections (from 5.3% in 2009 to 10.5% in 2014) while ESBL-K. pneumoniae 284 
remained stable.[23] Among South American countries, Argentina, along with Brazil, has 285 
experienced a statistical significant trend for carbapenem-resistant K. pneumoniae.[24, 25] 286 
According to the SENTRY study results from Latin America (2008-2010) rates of ESBL 287 
production were 24.7% among E. coli and 52.7% among K. pneumoniae.[25] 288 
 289 
In our cohort, BLBLIs, carbapenems and cephalosporins were the most frequently prescribed 290 
antibiotic classes for empirical monotherapy.  A significant proportion of empirical regimens 291 
were inadequate (50.6% of empirical regimens for ESBL-E and 76.4% for CPE; see Figure 2C 292 
and 2D), underscoring the difficulty in selecting appropriate empirical antimicrobial therapy 293 
in the context of MDR infections. However, it should be noted that some agents may still 294 
have some clinical efficacy (e.g. carbapenems against CPE) despite being categorised as ‘non-295 
susceptible’ according to clinical breakpoints, particularly if used in combination.     296 
 297 
Empirical combination therapy partially matches epidemiological data (i.e. countries with a 298 
high rate of carbapenem resistance are those which tend to use more combination 299 
therapies) but also with clinical presentation. Considering severity of disease at clinical 300 
presentation, the participant sites from Greece, Brazil, Argentina, Turkey and Italy were 301 




countries with >50% of patients presented with severe sepsis or septic shock, which may 302 
influence the use of combination empirical regimens.  Combination therapy is recommended 303 
by some for the treatment of serious infection due to MDR organisms, particularly for 304 
CPE[26] and inadequate empirical treatment has been shown to be associated with higher 305 
mortality.[27] 306 
 307 
The variation in BLBLI use for ESBL-E bacteraemia is notable.  Despite some observational 308 
data suggesting that BLBLI may be non-inferior to carbapenems in this context,[11, 28] it is 309 
clear that this practice was not widespread during the period of study in these countries.  310 
This may suggest that if robust clinical evidence emerges that indicates equivalent clinical 311 
efficacy for BLBLIs against ESBL-E, there may be considerable scope to reduce carbapenem 312 
use against these infections.  Studies have been conflicting in this area, with some 313 
observational data to suggest that empirical BLBLI is associated with increased mortality,[29] 314 
although this finding does not reflect the experience in other settings.[28] Given these 315 
uncertainties, the standard of care has relied upon carbapenems for serious ESBL-E 316 
infections.[3] However, with the international drive for improved antimicrobial stewardship, 317 
there is considerable interest to seek carbapenem-sparing options for ESBL-E infections.    318 
Use of targeted combination therapy for ESBL-E was relatively infrequent (21%, range 0 to 319 
31.6%) but may reflect lack of data suggesting benefit for such infections.  However, 320 
targeted combination therapy for CPE was more common (used in 44.1% overall, range 321 
13.3% [Taiwan] to 66.7% [Argentina]), probably reflecting limited effective treatment 322 
options, and some evidence that combination therapy may be of benefit.[30] However, 323 
when directed combination therapy was used for CPE, carbapenem-based regimens were 324 




less common than non-carbapenem-based options (17.3% vs 26.7%) (Supplementary Table 325 
1). 326 
 327 
Knowledge of historical clinical practice and the prevalence of MDR bacteria at a local level 328 
are both important when selecting antibiotic therapy. Scoring systems[31] have been 329 
studied to assess risk prediction for ESBL-E or CPE BSI.[32, 33] Factors such as poor 330 
functional status, recent antibiotic therapy or hospitalization and the severity of clinical 331 
presentation should be taken into account when assessing such risks. This can be 332 
challenging, especially in clinical settings where consultation with an infectious disease 333 
specialist is not readily available. Clinical risk-prediction scores also need to be adapted 334 
based on local prevalence. Hence, effective antimicrobial stewardship and the development 335 
of local guidelines, based on surveillance at an institutional and national level, are helpful to 336 
guide a prudent use of antimicrobials. In particular, the use of BLBLIs and carbapenems, two 337 
of the most frequently used classes for gram-negative BSI, has to be carefully balanced in an 338 
era where carbapenemases are increasingly encountered and alternatives therapies are 339 
currently limited.  340 
 341 
Our study has some limitations. As a post hoc analysis of a previously completed 342 
retrospective study, the original design was not intended to analyse epidemiological trends 343 
or variation in practice across countries.  The great majority of cases occurred in Spain, with 344 
relatively small numbers of cases and sites from other countries, which may introduce 345 
sampling bias.  Given the retrospective nature of the study, data were missing for some 346 
patients.  For some countries, the low proportion of CPE BSI reported did not reflect the 347 
known background prevalence of resistance, which may reflect sampling bias. For countries 348 




with few CPE cases, the study would be underpowered to detect regional differences in 349 
treatment selection. We did not look at the impact on mortality of different regimens 350 
between the countries as this question has been addressed elsewhere.[11] 351 
 352 
5. Conclusions 353 
In this international observational cohort of patients with bloodstream infections caused by 354 
multi-drug resistant Enterobacteriaceae, we observed a preference to treat ESBL-E BSI with 355 
carbapenems and CPE BSI with alternatives to carbapenems or combination therapy.  In 356 
some countries, such as Italy and Turkey, the likelihood of using empirical BLBLI for ESBL-E is 357 
significantly higher than in recruiting sites in other countries such as Israel, Greece and 358 
Canada.   Being treated in the participant sites from USA or Taiwan was independently 359 
associated with an increased likelihood of receiving empirical carbapenem therapy, whereas 360 
this strategy was used less in Canadian or Italian participating hospitals. It should be noted 361 
that, although this study does not provide accurate data on the relative prevalence of ESBL-E 362 
or CPE across countries, it does offer some insight into the antibiotic strategies used for 363 
these infections. Despite variation across countries in the prevalence of ESBL-E or CPE, which 364 
may drive antibiotic selection, additional factors beyond clinical presentation and illness 365 
severity influence selection of empirical and targeted therapy in multi-drug resistant gram-366 
negative bloodstream BSI.  Knowledge of regional differences in therapy for these infections 367 
will help design international clinical trials aiming to compare new treatment options for 368 
gram-negative BSI. Further research is needed to better understand the reasons for these 369 
differences in order to target antimicrobial stewardship efforts.    370 
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Figure 1:  Frequency of ESBL-E and CPE cases submitted by country 541 
Figure 2: Selection of empirical therapy for BSI by country. 2A| Empirical therapy for BSI 542 
caused by ESBL-E. 2B | Empirical therapy for BSI caused by CPE. 2C | Proportions of ESBL-E 543 
testing susceptible to the empirical regimen. 2D | Proportions of CPE testing susceptible to 544 
the empirical regimen 545 
Figure 3: Selection of empirical therapy for BSI caused by ESBL-E or CPE by source or 546 
acquisition status. 3A | Empirical therapy for ESBL-E by source of infections. 3B | Empirical 547 
therapy for CPE by source of infection. 3C | Empirical therapy for ESBL-E by acquisition 548 
status. 3D | Empirical therapy for CPE by acquisition status. 549 
Figure 4: Selection of targeted therapy for ESBL-E or CPE by country. 4A| Targeted therapy 550 
for BSI caused by ESBL-E. 4B | Targeted therapy for BSI caused by CPE. 4C | Proportions of 551 
ESBL-E cases treated with targeted combination therapy. 4D | Proportions of CPE cases 552 
treated with targeted combination therapy 553 
Figure 5: Forest plots of adjusted odd ratios (aOR) and 95% confidence intervals (95% CIs) for 554 
antibiotic selection by participating sites in each country. 5A | aORs for empirical use of 555 
BLBLI. 5B | aORs for empirical use of carbapenems. 5C | aORs for targeted use of BLBLI for 556 
ESBL-E. 5D | aORs for targeted use of combination therapy for CPE. Note: Spain used as a 557 
reference (full data in Supplementary tables 3-6) 558 
 559 
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Table 1: Baseline variables for patients with ESBL-E and CPE 561 
Variable  ESBL CPE P 
Gender Female 441 (44.0%) 200 (41.8%) 0.42¶ 
 Male 562 (56.0%) 279 (58.2%)  
Age, mean (SD)  65.8 (17.8) 62.9 (17.5) 0.003* 
Admission type Medical 465 (46.9%) 196 (41.6%) <0.001¶ 
 Surgical 138 (13.9%) 56 (11.9%)  
 ED 260 (26.2%) 51 (10.8%)  
 ICU 128 (12.9%) 168 (35.7%)  
Charlson score, median (IQR)  2.0 (1.0, 4.0) 2.0 (1.0, 4.0) 0.022§ 
Pitt score, median (IQR)  1.0 (0.0, 3.0) 3.0 (0.0, 5.0) <0.001§ 
Severe sepsis or shock Absent 605 (62.2%) 212 (46.6%) <0.001¶ 
 Present 367 (37.8%) 243 (53.4%)  
Acquisition Nosocomial 492 (50.1%) 426 (88.9%) <0.001¶ 
 Community 491 (49.9%) 53 (11.1%)  
Source Urinary 421 (42.1%) 73 (15.6%) <0.001¶ 
 Biliary 109 (10.9%) 21 (4.5%)  
 Intra-abdominal 115 (11.5%) 49 (10.4%)  
 Pneumonia 72 (7.2%) 52 (11.1%)  
 Osteoarticular 5 (0.5%) 0  
 Vascular 66 (6.6%) 105 (22.4%)  
 Skin / soft tissue 27 (2.7%) 16 (3.4%)  
 Central nervous system 2 (0.2%) 1 (0.2%)  
 Unknown 166 (16.6%) 135 (28.8%)  
 Others 16 (1.6%) 17 (3.6%)  
Species E. coli 693 (69.1%) 17 (3.5%) <0.001¶ 
 Klebsiella spp. 233 (23.2%) 415 (86.6%)  
 Others 77 (7.7%) 47 (9.8%)  
Diabetes Absent 661 (66.5%) 314 (67.7%) 0.66¶ 
 Present 333 (33.5%) 150 (32.3%)  
Liver disease Absent 857 (87.1%) 409 (86.8%) 0.89¶ 
 Present 127 (12.9%) 62 (13.2%)  
Malignancy Absent 594 (60.9%) 302 (64.3%) 0.22¶ 
 Present 381 (39.1%) 168 (35.7%)  
Renal dysfunction Absent 753 (78.6%) 348 (76.0%) 0.27¶ 
 Present 205 (21.4%) 110 (24.0%)  
Total  1003 479  
*2-sample t-test §Wilcoxon rank-sum test ¶ Pearson’s χ
2
 test 562 
 563 
 564 
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